Clinical trials: Esophageal Squamous Cell Carcinoma (ESCC), open to volunteers
Esophageal Squamous Cell Carcinoma (ESCC)
A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
Esophageal cancer is a high - incidence cancer type in China, characterized by high incidence, high mortality, and low survival rates.
- Trial name
- NCT06863831
- Testing
- Yishen Qutong Granules, Yishen Qutong Simulant Granules
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ESCC, Advanced Esophageal Squamous Cell Carcinoma
AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
This is a single arm，phase 2 study evaluating the safety and efficacy of Ivonescimab(AK112) combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06489197
- Testing
- Ivonescimab combined with albumin paclitaxel and cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The purpose of this study is to assess the efficacy and safety of QL1706 plus lenvatinib in second-line therapy for patients with metastatic esophageal squamous cell carcinoma after progression on immune checkpoint inhibitor…
- Trial name
- NCT06746961
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib
- Volunteers
- 49 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of sintilimab combined with chemotherapy, followed by sequential concurrent chemoradiotherapy as conversion therapy, in…
- Trial name
- NCT06709417
- Testing
- Sintilimab, Chemotherapy, radiotherapy
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Tumor Regression Grade As Predictor of Adjuvant Therapy
Neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma, but the necessity of adjuvant therapy remains controversial.
- Trial name
- NCT06710665
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fujian Medical University Union Hospital
Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
The aim of this clinical trial is to evaluate the efficacy and safety of consolidation therapy with a neoantigen-loaded dendritic cell vaccine (NeoDC-Vac) following radical chemoradiotherapy or chemoradiation-immunotherapy in…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT06675201
- Testing
- neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Sichuan University